NCT00290914|CompletedPhase 2
Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder
1 other identifier
PRI #608
Study Type
interventional
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredFeb 2006
Brief Summary
The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 9, 2006
Completed4 days until next milestone
First Posted
Study publicly available on registry
February 13, 2006
CompletedLast Updated
May 9, 2012
Status Verified
May 1, 2012
First QC Date
February 9, 2006
Last Update Submit
May 8, 2012
Conditions
Interventions
VilazodoneDRUG
Eligibility Criteria
Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
You may qualify if:
- Male or female patients 18-65 years of age, inclusive.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Depressive Disorder, Major
Interventions
Vilazodone Hydrochloride
Condition Hierarchy (Ancestors)
Depressive DisorderMood DisordersMental Disorders
Intervention Hierarchy (Ancestors)
PiperazinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsBenzofuransHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingIndoles
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Purpose
- TREATMENT
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 9, 2006
First Posted
February 13, 2006
Last Updated
May 9, 2012
Record last verified: 2012-05